Latest News

May 20, 2013

Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer(PDF)

April 18, 2013

Data Presented at OARSI’s 2013 World Congress on Osteoarthritis Show Flexion’s FX006 Has Prolonged Therapeutic Concentration in Knee Joint (PDF)

April 9, 2013

In Vivo: Reinventing Flexion for the world beyond Proof of Concept (PDF)

January 4, 2013

Flexion Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference (PDF)

December 17, 2012

Flexion’s FX006 Achieves Prolonged Therapeutic Concentrations in Joints of Osteoarthritis Patients (PDF)

December 4, 2012

Flexion Therapeutics Secures $20 Million in Series B Financing (PDF)

June 19, 2012

Flexion Therapeutics Names Arthur Fratamico (PDF)

May 30, 2012

Flexion’s Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial (PDF)

May 30, 2012

Trial Vets at Flexion claim PhII Success with Lead Osteoarthritis Drug, Fiercebiotech.com

May 30, 2012

Flexion Reports Positive Data for Osteoarthritis Drug, Masshightech.com

Clinical Trials

FX006: Phase IIb Dose Ranging Study, ClinicalTrials.gov

FX005: Proof of Concept Study, ClinicalTrials.gov

Media Inquiries

Matt Middleman or Tony Russo
Russo Partners LLC
Tel: 212 845 4272
Tel: 212 845 4251
Email:
matt.middleman@russopartnersllc.com
tony.russo@russopartnersllc.com